Sign In
Buy DMAC
$6.34
-0.170 (-2.61%)
At Close: Jul 31, 2026
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
04:15pm, Tuesday, 19'th Mar 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal
DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
04:13pm, Monday, 29'th Jan 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute
DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
08:23am, Monday, 22'nd Jan 2024
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal
DiaMedica Therapeutics Inc. (DMAC) Q3 2023 Earnings Call Transcript
12:10pm, Tuesday, 14'th Nov 2023
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q3 2023 Earnings Call Transcript November 14, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Particip
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
04:28pm, Monday, 13'th Nov 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
08:25am, Thursday, 09'th Nov 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
08:23am, Monday, 06'th Nov 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute
DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
08:13am, Tuesday, 12'th Sep 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal
DiaMedica Therapeutics to Participate at Lake Street's 7th Annual Best Ideas Growth Conference
08:35am, Wednesday, 06'th Sep 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders, today announced
Is DiaMedica Therapeutics (DMAC) Stock Outpacing Its Medical Peers This Year?
11:17am, Thursday, 31'st Aug 2023
Here is how DiaMedica Therapeutics, Inc. (DMAC) and DermTech, Inc. (DMTK) have performed compared to their sector so far this year.
DiaMedica Therapeutics Inc. (DMAC) Q2 2023 Earnings Call Transcript
03:43pm, Tuesday, 15'th Aug 2023
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q2 2023 Earnings Call Transcript August 15, 2023 8:00 AM ET Company Participants Rick Pauls - President and CEO Scott Kellen - CFO Conference Call Participan
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results
04:13pm, Monday, 14'th Aug 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal
DiaMedica Therapeutics to Report Second Quarter 2023 Financial Results and Provide a Business Update August 15, 2023
08:32am, Tuesday, 08'th Aug 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute
DiaMedica Therapeutics Inc. (DMAC) Q1 2023 Earnings Call Transcript
09:11am, Tuesday, 16'th May 2023
DiaMedica Therapeutics Inc. (NASDAQ:DMAC ) Q1 2023 Earnings Conference Call May 16, 2023 8:00 AM ET Company Participants Rick Pauls - President and Chief Executive Officer Scott Kellen - Chief Financi
DiaMedica Therapeutics to Report First Quarter 2023 Financial Results and Provide a Business Update May 16, 2023
08:50am, Monday, 08'th May 2023
MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute
